德琪医药-B(06996):希维奥®获批纳入台湾全民健康保险

智通财经网
13 Feb

智通财经APP讯,德琪医药-B(06996)公布,希维奥® (塞利尼索)(与硼替佐米和地塞米松(XVd)联用,用于治疗既往接受过至少两种治疗的复发╱难治性多发性骨髓瘤 (rrMM)成年患者)已在台湾获批纳入全民健康保险。自2025年3月1日起,希维奥®将获正式纳入台湾《全民健康保险用药品项表》。

更多港股重磅资讯,下载智通财经app

更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10